Pipeline

Filter by:
All disease areas
  • All disease areas
  • Alzheimer's Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Epilepsy
  • Fibrosis
  • Lupus
  • Lymphoma
  • Multiple Sclerosis (MS)
  • Ophthalmology
  • Pain
  • Parkinson's Disease
  • Progressive Supranuclear Palsy (PSP)
  • Schizophrenia
  • Spinal Muscular Atrophy (SMA)
  • Stroke
All phases
  • All phases
  • Filed
  • Phase 3
  • Phase 2
  • Phase 1
Phase
  • 1Phase 1
  • 2 Phase 2
  • 3Phase 3
  • Filed
  • Aducanumab (Aβ mAb)

    Alzheimer’s disease

    Developed in collaboration with Neurimmune.

    Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1.

    Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.

     

    How this investigational therapy could help:

    The memory loss and functional decline of Alzheimer’s disease have been linked to amyloid plaques, abnormal protein deposits that build up in  the brain. Aducanumab is an antibody that binds to and may reduce amyloid plaques from the brain, potentially slowing the progress of the disease.

    Learn more about EMERGE and ENGAGE, clinical trials for Alzheimer’s disease

     

    1 World Health Organization Dementia a Public Health Priority. http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed 23 May 2016.

  • BIIB098 (monomethyl fumarate prodrug)

    Multiple sclerosis (MS)

    Licensed from Alkermes.

    This disease causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking. Over time, the nerves themselves can become damaged permanently.

     

    How this investigational therapy could help:

    BIIB098 (monomethyl fumarate prodrug) is a monomethyl fumarate (MMF) prodrug investigational candidate designed to rapidly and efficiently convert to MMF in the body and may offer differentiated features as compared to the currently marketed dimethyl fumarate.

  • E2609 (BACE1 inhibitor)

    Alzheimer's disease

    Developed in collaboration with Eisai Co., Ltd.

    Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1.

    Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.

     

    How this investigational therapy could help:

    The memory loss and functionality decline of Alzheimer’s disease have been linked to amyloid plaques, abnormal protein deposits that build up in the brain. E2609 is a small-molecule inhibitor of beta-secretase, a protein that cleaves enzyme 1 (BACE1). By inhibiting BACE1, E2609 blocks amyloid production, potentially slowing the progress of the disease.

    1 World Health Organization Dementia a Public Health Priority. http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed 23 May 2016.

  • BAN2401 (Aβ mAb)

    Alzheimer’s disease

    Developed in collaboration with Eisai Co., Ltd.

    Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1.

    Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.

     

    How this investigational therapy could help:

    The memory loss and functionality decline of Alzheimer’s disease have been linked to amyloid plaques, abnormal protein deposits that build up in the brain. BAN2401 is an antibody that binds to amyloid, which could reduce its presence in the brain and potentially slow the progress of the disease.

     

    1 World Health Organization Dementia a Public Health Priority. http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed 23 May 2016.

  • BG00011 (STX-100)

    Idiopathic pulmonary fibrosis (IPF)

    Pulmonary fibrosis is a disease in which lung tissue becomes thickened and stiff due to scarring. The formation of scar tissue is called fibrosis. As the disease progresses, it becomes harder for the lungs to work properly and the body cannot get the oxygen it needs. This debilitating disease is almost always fatal.

     

    How this investigational therapy could help:

    The TGF-beta brain cell pathway is involved in several fibrotic diseases. The BG00011 (STX-100) antibody may selectively block the TGF-beta pathway, and may slow the development of fibrosis in IPF patients.

  • BIIB054 (anti-α-synuclein)

    Parkinson's disease

    Acquired from Neurimmune.

    Parkinson's disease is a disorder of the central nervous system. People who have this disease experience tremors, slow movement, muscle stiffness, and impaired balance.  As these symptoms become progressively worse, patients have difficulty walking, talking, or completing other simple tasks.

     

    How this investigational therapy could help:

    BIIB054 targets abnormal alpha-synuclein protein that is associated with the destruction of nerve cells. This progressive degeneration is the cause of Parkinson's disease.

    Learn more about SPARK, a clinical trial for Parkinson’s disease

  • BIIB059 (anti-BDCA2)

    Lupus

    This chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin, joints, kidneys, the brain and other organs. It is a difficult disease to diagnose because it resembles several other conditions.

     

    How this investigational therapy could help:

    BDCA2 is a protein present in specific cells within the immune system. An antibody against BDCA2 can potentially interrupt production of interferons, inflammatory molecules that are increased in patients with lupus and contribute to disease activity. 

  • BIIB074 (vixotrigine)

    Trigeminal neuralgia (TGN)

    Trigeminal neuralgia is an extremely painful rare condition usually involving one side of the face. Trigeminal neuralgia is characterized by sudden, brief, stabbing, recurrent episodes of pain which frequently occurs spontaneously but is also commonly evoked by trivial stimuli including washing, talking or brushing the teeth (trigger factors). The pain follows one or more branches of the trigeminal nerve, which provides nerve sensation from the mouth, face and the front of the scalp. The intensity, frequency and unpredictability of the pain results in profound effects on the quality of life of patients and their caregivers.

     

    How this investigational therapy could help:

    BIIB074 (vixotrigine) is a centrally and peripherally acting, small-molecule, which is a selective, state-dependent Nav1.7 sodium channel blocker for trigeminal neuralgia. 

  • BIIB074 (vixotrigine)

    Painful lumbosacral radiculopathy (PLSR)

    Lumbosacral radiculopathy (PLSR) is pain due to both inflammation and nerve pain. Patients usually have low back pain due to degenerative changes of the spine or intervertebral discs with resulting inflammation, as well as nerve pain originating in a compressed spinal nerve which travels from the buttocks down one or both legs. 

     

    How this investigational therapy could help:

    BIIB074 is a centrally and peripherally acting, small-molecule, which is a selective, state-dependent Nav1.7 sodium channel blocker for painful lumbosacral radiculopathy (PLSR).

    Learn more about the clinical trial for BIIB074 in PLSR

  • BIIB087 (XLRS Gene Therapy)

    X-linked retinoschisis (XLRS)

    Developed in collaboration with AGTC

    XLRS is a disease that affects young males beginning in their teenage years. It can lead to loss of vision and serious complications such as vitreous hemorrhage or retinal detachment during adulthood.

     

    How this investigational therapy could help:

    BIIB087 is a recombinant adeno-associated virus vector (rAAV) delivering a transgene (RS1) that expresses retinoschisin protein. Normal expression of retinoschisin could potentially improve long-term retinal function and preserve structural integrity.

  • BIIB088

    X-linked Retinitis Pigmentosa (XLRP)

    Applied Genetic Technologies Corporation (AGTC)

     

    X-linked Retinitis Pigmentosa (XLRP) is an inherited condition that causes progressive vision loss in boys and young men. Characteristics of the disease include night blindness in early childhood and progressive constriction of the visual field. In general, XLRP patients experience a gradual decline in visual acuity over the disease course, which results in legal blindness around the 4th decade of life.

    BIIB088 is a Phase 1/2 study.

     

    How this investigational therapy could help:

    BIIB088 is an investigational gene therapy being evaluated in patients with XLRP.

    Learn more about the clinical trial for BIIB088 in XLRP

  • BIIB092

    Progressive supranuclear palsy (PSP)

    Licensed from Bristol-Myers Squibb.

    Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease that affects adults. This devastating disease typically advances quickly and affects movement, speech, vision and cognitive function. Currently, there are no effective therapies for PSP.

     

    How this investigational therapy could help:

    In PSP, deposits of abnormal tau, so-called neurofibrillary tangles, form within neurons and are linked to increasing impairment and loss of brain cells. BIIB092 is an antibody targeting extracellular tau which may reduce the spreading of the abnormal form of this molecule from one nerve cell to the next, potentially slowing the progression of the disease.

    Learn more about PASSPORT, a clinical trial for PSP

     

  • BIIB093 (glibenclamide IV)

    Stroke

    It is estimated that nearly two million people in the United States and the European Union will have a stroke each year. Stroke is a leading cause of mortality and serious long-term disability. There is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke. The target indication for BIIB093 (glibenclamide IV) is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality.

     

    How this investigational therapy could help:

    In pre-clinical studies, BIIB093 (glibenclamide IV) has been shown to block SUR1-TRPM4 channels that mediate stroke related brain swelling. Clinical proof-of-concept studies have demonstrated the potential of BIIB093 to reduce brain swelling, disability and the risk of death in patients with LHI.

  • BIIB104

    Cognitive impairment associated with schizophrenia (CIAS)

    Acquired from Pfizer Inc. 

    Worldwide there are greater than 20 million people living with schizophrenia and it is estimated that the majority of them live with some degree of cognitive impairment attributable to the disease. When cognition is impaired, processing information, planning, and remembering become difficult or impossible. Cognition can be impaired in multiple neurological and neuropsychiatric diseases, including schizophrenia. 

    BIIB104 is a first-in-class, Phase 2b ready asset for CIAS

     

    How this investigational therapy could help:

    BIIB104 is an AMPA receptor potentiator designed to facilitate neurotransmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia.

     

  • Dapirolizumab pegol (anti-CD40L)

    Lupus

    Developed in collaboration with UCB, Inc.

    This chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin, joints, kidneys, the brain and other organs. It is a difficult disease to diagnose because it resembles several other conditions.

     

    How this investigational therapy could help:

    CD40L is a protein in B and T cells, which helps regulate the immune system. Dapirolizumab pegol (anti-CD40L) is an antibody that blocks CD40L, potentially lessening disease activity in lupus patients.

  • Natalizumab (α4-integrin inhibitor)

    Drug resistant focal epilepsy

    Focal epilepsy is the most common form of epilepsy and is characterized by seizures resulting from abnormal signaling in one region of the brain. Epilepsy is estimated to be the fourth most common neurological disease, affecting 3.4 million people in the US. Given the morbidity and mortality associated with uncontrolled epilepsy, drug-resistant epilepsy patients have a high degree of unmet need.

     

     

    How this investigational therapy could help:

    Natalizumab is being investigated as an adjunctive therapy in the treatment of adult patients with drug-resistant focal epilepsy.

    Learn more about the clinical trial for natalizumab in drug resistant focal epilepsy

     

  • Opicinumab (anti-LINGO)

    Multiple sclerosis (MS)

    This disease causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking. Over time, the nerves themselves can become damaged permanently.

     

    How this investigational therapy could help:

    LINGO-1 is a CNS specific-protein that is involved in the development of myelin. In patients with MS, LINGO-1 may inhibit myelin growth when it binds with its receptor. Data suggest that the antibody anti-LINGO-1 could block this process, potentially allowing for the re-myelination and restoration of nerve communication in MS patients.

  • BIIB067 (IONIS-SOD-1Rx)

    SOD-1-Amyotrophic lateral sclerosis (ALS)

    Developed in collaboration with Ionis Pharmaceuticals.

    ALS is a progressive neurodegenerative disease that results in the loss of motor neurons in the brain and the spinal cord. Motor neurons provide the ability to move, speak, swallow, and breathe. As the disease progresses, ALS patients gradually lose these abilities.

     

    How this investigational therapy could help: 

    In a rare form of ALS, a mutated protein called superoxide dismutase (SOD1) has been associated with the degeneration of motor neurons.  SOD1-ALS is the second most common form of inherited or familial ALS, accounting for up to 20 percent of familial ALS and 2 percent of all ALS cases. 

    BIIB067 (IONIS-SOD-1Rx) is thought to reduce the production of SOD1 protein and is being evaluated to see if it can potentially slow the fatal progression of SOD1-ALS.

  • BIIB076

    Alzheimer's disease

    Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1.

    Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.

     

    How this investigational therapy could help:

    The memory loss and functional decline of AD have been linked to abnormal protein deposits that build up in the brain. Among those proteins are amyloid and tau. Deposits of abnormal tau, so-called neurofibrillary tangles, form in the neurons and are linked to increasing impairment and loss of brain cells associated both with AD and with other neurodegenerative diseases, known as tauopathies, such as progressive supranuclear palsy and frontotemporal dementia. BIIB076 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain.

    1 World Health Organization Dementia a Public Health Priority. http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed 23 May 2016.

  • BIIB080 (IONIS-MAPTRx)

    Alzheimer's disease

    Developed in collaboration with Ionis Pharmaceuticals.

    Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1. Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.

     

    How this investigational therapy could help:

    The memory loss and functional decline of Alzheimer’s disease have been linked to amyloid plaques and tau tangles, abnormal protein deposits that build up in the brain and in the brain cells. BIIB080 (IONIS-MAPTRx) is an antisense oligonucleotide (ASO) that may reduce production of the tau protein and its accumulation in brain cells, potentially slowing the progress of the disease.

    Learn more about the BIIB080 (IONIS-MAPTRx) clinical trial

    1World Health Organization Dementia a Public Health Priority. http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed 23 May 2016. 

  • BIIB092

    Alzheimer's disease

    Licensed from Bristol-Myers Squibb.

    Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1.

    Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.

     

    How this investigational therapy could help:

    The memory loss and functional decline of AD have been linked to abnormal protein deposits that build up in the brain. Among those proteins are amyloid and tau. Deposits of abnormal tau, so-called neurofibrillary tangles, form in the neurons and are linked to increasing impairment and loss of brain cells associated both with AD and with other neurodegenerative diseases, known as tauopathies, such as progressive supranuclear palsy and frontotemporal dementia. BIIB092 is an antibody targeting extracellular tau and may reduce the spreading of tau from one cell to the next, potentially slowing the progress of the disease.

    1 World Health Organization Dementia a Public Health Priority. http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed 23 May 2016.

  • BIIB095

    Neuropathic pain

    Neuropathic pain affects more than 12 million adults in the US, and is a type of chronic pain that occurs when nerves in the central nervous system become injured or damaged. These damaged nerve fibers send incorrect signals to other pain centers. The impact of a nerve fiber injury includes a change in nerve function both at the site of injury and areas around the injury. 

     

    How this investigational therapy could help:

    BIIB095 is a next-generation Nav 1.7 inhibitor for neuropathic pain. Nav1.7 is a genetically-validated key pain target, with gain-of function mutations linked to severe chronic pain syndromes and loss-of-function mutations linked to the inability to sense pain.

    Learn more about the clinical trial BIIB095 in neuropathic pain

Currently no results for this search